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apping Directions for
he Cardiorenal Conundrum
here You End Up
epends Upon Where You Started,
o Where Do We Go From Here?*
arry A. Weinrauch, MD, FACC,†
ulie Lin, MD, MPH,‡ Scott D. Solomon, MD§
oston and Cambridge, Massachusetts
arkedly depressed cardiac function may be associated
ith decreased glomerular filtration rate (GFR) as renal
erfusion diminishes; conversely, lower GFR has been
ssociated with increased risk for cardiovascular events in
opulation studies (1) and in studies of patients with
ystolic dysfunction (2,3), coronary artery disease (4), or
eart failure (5). Moreover, worsening of renal function
as been associated with adverse prognosis in heart
ailure (HF) patients (6,7). The exact mechanisms by
hich renal dysfunction contributes to increased cardio-
ascular risk remain to be elucidated.
See page 1268
Current management of symptomatic HF exacerbations
s focused on reduction of both pre-load and afterload, the
ormer accomplished primarily through pharmacologic fluid
emoval and venodilator drugs, with volume removal
hrough ultrafiltration an option in the most critically ill
atients, and the latter accomplished through the use of
asodilator agents, primarily inhibitors of the renin-
ngiotensin-aldosterone system (RAAS). All of these ap-
roaches have the potential to increase serum creatinine
SCr) and lead to worsening renal function. Nevertheless,
nhibition of the RAAS, an approach that can reliably
ncrease SCr, has been shown to retard the progression of
enal disease and improve cardiovascular outcomes in pa-
ients with reduced renal function (8,9).
It is not uncommon for clinicians to respond to progres-
ive SCr elevation with reduction or cessation of diuretics or
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Joslin Diabetes Center and Mt. Auburn Hospital, Boston andd
ambridge, Massachusetts; and the ‡Renal and §Cardiovascular Divisions, Brigham
nd Women’s Hospital, Harvard Medical School, Boston, Massachusetts.nhibitors of the RAAS in HF patients. However, whether
lterations in pharmacologic management—particularly di-
retics—are warranted in the setting of creatinine elevation
emains unclear. The data from the ESCAPE (Evaluation
tudy of Congestive heart failure And Pulmonary artery
atheterization Effectiveness) trial published in this issue of
he Journal (10) adds further insight into problems faced by
linicians when a patient with systolic dysfunction (ejection
raction 30%) presents with HF and renal dysfunction.
he ESCAPE trial was designed to assess whether the use
f pulmonary artery hemodynamic measurements in the
reatment of HF patients would improve overall morbidity
nd mortality over 6 months. In this study of 433 hospital-
zed patients, mean SCr on admission was 1.5 mg/dl
maximum SCr 3.5 mg/dl and admission systolic blood
ressure 125 mm Hg), and estimated baseline GFR was
60 ml/min in 117 (27%) patients. This secondary analysis
ocused on the relationship between baseline and in-hospital
hanges in SCr and estimated GFR and death and rehos-
italization at 6 months. Predictors of interest for patient
utcomes at 6 months included SCr and estimated GFR at
dmission, changes in renal function during hospitalization,
se of diuretics and vasodilators during the hospitalization,
nd treatment assignment.
While the findings suggest that baseline GFR was pre-
ictive of outcome, as has been shown in prior studies,
levation of SCr 0.03 mg/dl, the standard definition of
orsening renal function (6,7), during hospitalization had less
mpact on prognosis than did baseline renal function. There are
number of potential explanations for these results. First, a
hange in SCr from 1.5 to 1.8 mg/dl represents a greater
bsolute loss of renal function than a change from 3.0 to 3.3
g/dl. Therefore, the impact of a0.3 mg/dl rise in SCr may
iffer based on baseline renal function. Second, elevations in
Cr may have different prognostic implications depending on
he patient population and therapies utilized. In patients with
F, aggressive use of diuretics and inhibitors of the RAAS,
hich may improve both symptoms and possibly outcomes, are
ikely to result in increases in SCr. Indeed, in a randomized
rial comparing the angiotensin-converting enzyme inhibitor
aptopril to placebo in patients with systolic dysfunction after
yocardial infarction, worsening renal function—defined in
he same way as in ESCAPE—was associated with adverse
utcomes in patients randomized to the placebo group, but not
n patients receiving captopril (11).
The authors suggest that “risk factors for renal disease
robably make the kidney more susceptible to cardiac
ompromise” (10). We can also speculate that normal
ompensatory mechanisms that maintain GFR are over-
helmed by the circulatory changes that occur in HF
hen intrinsic renal disease is present, as it almost
ertainly is in most of these patients since hemodynamic
arameters of poor forward flow correlated poorly with
aseline renal dysfunction. History of hypertension or
iabetes (both conditions that promote progressive renal
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Editorial Comment April 1, 2008:1275–6carring) and thiazide use (whose addition to loop diuret-
cs is often needed to promote adequate diuresis in
atients with chronic kidney disease) was also signifi-
antly associated with worsening of renal function, and
rovides further evidence that many in this study cohort
ad covert intrinsic kidney disease.
If elevations in SCr are less important than initial renal
unction in HF patients, should we continue to withdraw
eneficial medications in the setting of moderate increases
n SCr levels in the absence of uremic symptoms, or would
ur patients benefit to a greater extent from a strategy of
ptimizing hemodynamics? Further diuresis in the HF
atients whose creatinine has increased might still lead to
educed atrial stretch, lower brain natriuretic peptide, and
educed tendency to atrial arrhythmias. The cardiology
ommunity has been skittish in general about utilizing
roven medication, including angiotensin-converting en-
yme inhibitors and angiotensin receptor blockers, in the
etting of renal dysfunction, despite encouragement and
vidence from the renal community. Still, creatinine eleva-
ions may increase the risk of adverse events such as
ypotension or hyperkalemia (12), and heightened surveil-
ance is warranted in this setting.
Nohria et al. (10) underscore the extremely high
orbidity and mortality in those with cardiorenal disease.
hese data reinforce the need for further basic research to
larify the mechanisms that underlie the increased risk
ssociated with renal dysfunction along with well-
esigned clinical studies to further explore the implica-
ions of medical interventions in patients with both heart
nd kidney disease.
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